Biliary tract infections (BTI), often linked to structural abnormalities like bile duct stones, pose significant treatment challenges due to drug-resistant bacteria like Pseudomonas aeruginosa. Phage ...

Compass Therapeutics has announced top-line data from its ongoing COMPANION-002 trial investigating its antibody-based ...

Treatment with tovecimig, formerly known as CTX-009, elicited responses in patients with biliary tract cancer, according to ...

The primary end point of overall response rate has been met in the COMPANION-002 trial of tovecimig and paclitaxel in ...

Tovecimig, formerly known as CTX-009, is a bispecific antibody that blocks the Delta-like ligand 4 and vascular endothelial growth factor A signaling pathways.

Researchers laid out nutritional management strategies for clinicians to offer patients before and after bariatric surgery to ...

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one ...

Compass Therapeutics, Inc. (NASDAQ:CMPX) announced statistically significant topline data on Tuesday on the primary efficacy ...

Compass Therapeutics (CMPX) announced statistically significant top-line data on the primary efficacy endpoint for COMPANION-002, the Company’s ...